News
ARGNF
840.00
NaN%
--
HQH: Seeing Strong Recent Returns While Attractively Discounted
Seeking Alpha · 11/17 15:24
Baron International Growth Fund Q3 2025 Contributors And Detractors
Seeking Alpha · 11/06 10:40
Argenx outlines five registrational readouts in 2026 while expanding VYVGART global reach
Seeking Alpha · 10/30 20:27
Tracking Baker Brothers Portfolio - Q2 2025 Update
Seeking Alpha · 09/16 00:21
Weekly Report: what happened at ARGNF last week (0908-0912)?
Weekly Report · 09/15 11:17
argenx: Bullish On This R&D Focused Biotech Stock
Seeking Alpha · 09/12 08:16
Weekly Report: what happened at ARGNF last week (0901-0905)?
Weekly Report · 09/08 11:20
Weekly Report: what happened at ARGNF last week (0825-0829)?
Weekly Report · 09/01 11:15
Weekly Report: what happened at ARGNF last week (0818-0822)?
Weekly Report · 08/25 11:26
Artisan Global Opportunities Fund Q2 2025 Commentary
Seeking Alpha · 08/19 11:05
Weekly Report: what happened at ARGNF last week (0811-0815)?
Weekly Report · 08/18 11:18
Artisan International Fund Q2 2025 Commentary
Seeking Alpha · 08/14 03:25
Artisan Mid Cap Fund Q2 2025 Commentary
Seeking Alpha · 08/14 03:15
Artisan Global Discovery Fund Q2 2025 Commentary
Seeking Alpha · 08/14 02:15
Weekly Report: what happened at ARGNF last week (0804-0808)?
Weekly Report · 08/11 11:25
Baron Health Care Fund Q2: Top Contributors, Misses, And Strategic Shifts
Seeking Alpha · 08/08 01:35
Baron Opportunity Fund Q2 2025 Shareholder Letter
Seeking Alpha · 08/06 10:46
Why Johnson & Johnson Stock Still Has Room To Run
Seeking Alpha · 08/04 21:12
Janus Henderson European Focus Fund Q2 2025 Commentary
Seeking Alpha · 08/04 18:55
Weekly Report: what happened at ARGNF last week (0728-0801)?
Weekly Report · 08/04 11:28
More
Webull provides a variety of real-time ARGNF stock news. You can receive the latest news about Argen X through multiple platforms. This information may help you make smarter investment decisions.
About ARGNF
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.